Anti-SARS-CoV-2 Spike Glycoprotein RBD Antibody [2G1]

The 2G1 monoclonal antibody against SARS-CoV-2 spike glycoprotein RBD is a valuable tool for researchers seeking to understand the intricacies of COVID-19 infection. This uncojugated primary antibody is optimized for Western blotting and immunocytochemistry/immunofluorescence applications, ensuring precise results in various scientific studies. By leveraging its specificity towards the RBD domain of the SARS-CoV-2 spike protein, this antibody helps elucidate the mechanisms behind viral entry and host cell interaction.

Built for Reliable Primary Antibodies Performance

• Packaged in 100 µL aliquots at 1 mg/mL concentration to minimize freeze-thaw cycles.
• Suitable for various experimental setups, including 96-well plate assays and tissue culture plates.
• Ideal for researchers working with small sample volumes due to its high sensitivity.
• The 2G1 clone ensures consistent performance across different experiment types.
• Compatible with standard laboratory protocols and equipment.

Performance You Can Count On

Anti-Sars-Cov-2 Spike Glycoprotein Rbd Antibody [2G1] is listed under Primary Antibodies with the pack size and title shown on this page.

Versatile Uses of the Product

• Primary Antibodies tasks that call for Anti-Sars-Cov-2 Spike Glycoprotein Rbd Antibody [2G1] by name and pack size.
• Facilities already using Primary Antibodies products comparable to Anti-Sars-Cov-2 Spike Glycoprotein Rbd Antibody [2G1].
• Operations planning around the container format shown for Anti-Sars-Cov-2 Spike Glycoprotein Rbd Antibody [2G1].
• Maintenance cycles that include Anti-Sars-Cov-2 Spike Glycoprotein Rbd Antibody [2G1] in the supply list.